MIL •
Healthcare •
Biotechnology •
Quote as of 05/12/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeMIL
Market Capitalization790.23 mln
Float534 mln
Earnings Date05/06/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
-1.58
Likely manipulated
Relative Strength
10
/ 100
Significantly lagging
Debt / Equity
0.54
Moderate leverage
ROE
-31.81
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Geron Corporation is a California-based biopharmaceutical company founded in 1990 that develops treatments for blood cancers and related conditions. Its approved product, RYTELO, is used to treat a type of bone marrow disorder called myelodysplastic syndrome, and the company has several other treatments currently being tested in clinical trials targeting similar diseases, including myelofibrosis and acute myeloid leukemia.
